# VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

> **NCT00431353** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 325 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** Ganciclovir
- **DRUG:** valganciclovir [Valcyte]

## Key facts

- **NCT ID:** NCT00431353
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431353, "VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00431353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*